NEOSTREP

Development of Group B Streptococcal vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention

Coordinatore	LUNDS UNIVERSITET    more  Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Mrs. Nome: Stina Cognome: Ahlenius Email: send email Telefono: +46 46173465 Fax: +46 46130064
Nazionalità Coordinatore	Sweden [SE]
Sito del progetto	http://www.neostrep.eu
Totale costo	7˙969˙300 €
EC contributo	5˙999˙172 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-07-01   -   2016-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	LUNDS UNIVERSITET  Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Mrs. Nome: Stina Cognome: Ahlenius Email: send email Telefono: +46 46173465 Fax: +46 46130064	SE (LUND)	coordinator	1˙050˙734.50
2	MINERVAX APS  Organization address address: VEDBENDVEJ 28 city: HELLERUP postcode: 2900 contact info Titolo: Dr. Nome: Per Cognome: Fischer Email: send email Telefono: +45 20252038	DK (HELLERUP)	participant	3˙124˙600.00
3	BIO-KINETIC EUROPE LIMITED  Organization address address: GREAT VICTORIA STREET 14 city: BELFAST postcode: BT2 7BA contact info Titolo: Mr. Nome: Crawford Cognome: Maclean Email: send email Telefono: +44 2890818381 Fax: +44 2890238123	IE (BELFAST)	participant	1˙624˙077.00
4	CITOXLAB SCANTOX AS  Organization address address: Hestehavevej 36A city: Lille Skensved postcode: 4623 contact info Titolo: Mr. Nome: Andrew Cognome: Makin Email: send email Telefono: +45 56 86 15 26 Fax: +45 56 92 12 02	DK (Lille Skensved)	participant	199˙760.50

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The NeoStrep project will develop a novel vaccine against Group B Streptococcal (GBS) infections, responsible for 50% of life-threatening infections in newborns. The aim is to provide a safe and effective alternative to current generally implemented antibiotic prophylaxis. Emergence of clinical isolates of GBS with reduced susceptibility to penicillin (the preferred prophylactic antibiotic) and pattern of genetic mutations in penicillin binding proteins of GBS is identical to that observed in Streptococcus pneumoniae prior to the breakthrough of true widespread penicillin resistance in that pathogen. Combined with already existing resistance to a wide range of other antibiotics, this indicates current GBS antibiotic prophylaxis is highly vulnerable to antibiotic resistance. Emergence of widespread antibiotic resistance threatens to return the incidence of GBS disease to pre-prophylaxis levels with the associated significant increases in health cost and morbidity/mortality caused by infections with resistant GBS.

The NeoStrep project aims to eliminate the use of prophylactic antibiotics in GBS prevention and hence the problem of emerging antibiotic resistance in GBS through the development of a GBS vaccine.

No approved vaccine currently exists, and one currently in development only covers a subset of clinical serotypes. The NeoStrep vaccine, which is based on a novel fusion protein approach, has a wider serotype coverage (95%) and is much cheaper to manufacture than the other GBS vaccine candidate in development. The vaccine is extensively validated in animal models, and a simple production method has been developed.

The objective of the project is therefore to advance the vaccine through cGMP production, tox studies and into clinical trials, with the aim of generating proof of concept in humans by means of immunogenicity, response rate, durability and effect on spontaneous vaginal colonisation.'